- Home
- XAIR vs MBRX Comparison
XAIR vs MBRX Comparison
Compare XAIR & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- MBRX
- Stock Information
- Founded
- XAIR 2011
- MBRX 2015
- Country
- XAIR United States
- MBRX United States
- Employees
- XAIR N/A
- MBRX N/A
- Industry
- XAIR Medical/Dental Instruments
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- MBRX Health Care
- Exchange
- XAIR Nasdaq
- MBRX Nasdaq
- Market Cap
- XAIR 17.0M
- MBRX 17.1M
- IPO Year
- XAIR N/A
- MBRX 2016
- Fundamental
- Price
- XAIR $2.25
- MBRX $0.57
- Analyst Decision
- XAIR Strong Buy
- MBRX Strong Buy
- Analyst Count
- XAIR 1
- MBRX 3
- Target Price
- XAIR $11.00
- MBRX $5.33
- AVG Volume (30 Days)
- XAIR 190.1K
- MBRX 2.5M
- Earning Date
- XAIR 08-12-2025
- MBRX 08-12-2025
- Dividend Yield
- XAIR N/A
- MBRX N/A
- EPS Growth
- XAIR N/A
- MBRX N/A
- EPS
- XAIR N/A
- MBRX N/A
- Revenue
- XAIR $4,782,000.00
- MBRX N/A
- Revenue This Year
- XAIR $266.61
- MBRX N/A
- Revenue Next Year
- XAIR $140.76
- MBRX N/A
- P/E Ratio
- XAIR N/A
- MBRX N/A
- Revenue Growth
- XAIR 168.20
- MBRX N/A
- 52 Week Low
- XAIR $2.02
- MBRX $0.25
- 52 Week High
- XAIR $13.52
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- XAIR 35.48
- MBRX 43.74
- Support Level
- XAIR $2.02
- MBRX $0.54
- Resistance Level
- XAIR $2.42
- MBRX $0.61
- Average True Range (ATR)
- XAIR 0.20
- MBRX 0.05
- MACD
- XAIR -0.04
- MBRX -0.01
- Stochastic Oscillator
- XAIR 17.97
- MBRX 14.53
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.